Biocept, Inc. Sets Price Range on Proposed IPO; Anticipates $17.7 Million in Net Proceeds
Published: Nov 07, 2013
Biocept Sets Price Range on Proposed IPO; Anticipates $17.7M in Net Proceeds
Biocept today set the price range on its planned initial public offering, saying it expects to price its shares between $10 and $12. In its amended Form S-1 filed on Tuesday with the US Securities and Exchange Commission, the circulating tumor cell diagnostics firm said that it expects to offer about 1.8 million shares of its common stock, netting proceeds of approximately $17.1 million at the midpoint price of $11 per share. It would net $20.5 million if the underwriters exercise their overallotment option in full.
Help employers find you! Check out all the jobs and post your resume.